Puma Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 04, 2021 at 04:31 pm EDT
Share
Puma Biotechnology, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 46.25 million compared to USD 50.75 million a year ago. Net loss was USD 44.67 million compared to USD 31.46 million a year ago. Basic loss per share from continuing operations was USD 1.09 compared to USD 0.79 a year ago. Diluted loss per share from continuing operations was USD 1.09 compared to USD 0.79 a year ago.
For the nine months, revenue was USD 197.8 million compared to USD 172.55 million a year ago. Net loss was USD 33.35 million compared to USD 45 million a year ago. Basic loss per share from continuing operations was USD 0.82 compared to USD 1.14 a year ago. Diluted loss per share from continuing operations was USD 0.82 compared to USD 1.14 a year ago.
Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
PUMA BIOTECHNOLOGY, INC. 
